Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 168

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

3023 Mayo Clinic Patients With Myeloproliferative Neoplasms: Risk-Stratified Comparison of Survival and Outcomes Data Among Disease Subgroups

Szuber, Natasha, Mudireddy, Mythri, Nicolosi, Maura, Penna, Domenico, Vallapureddy, Rangit R., Lasho, Terra L., Finke, Christy, Begna, Kebede H., Elliott, Michelle A., Hook, C. Christopher, Wolanskyj, Alexandra P., Patnaik, Mrinal M., Hanson, Curtis A., Ketterling, Rhett P., Sirhan, Shireen, Pardanani, Animesh, Gangat, Naseema, Busque, Lambert, Tefferi, Ayalew · 2019 · Mayo Clinic Proceedings

Abstract

Objective: To document the Mayo Clinic decades‐long experience with myeloproliferative neoplasms (MPNs) and provide mature risk‐stratified survival data and disease complication estimates. Patients and Methods: All Mayo Clinic patients with World Health Organization–defined MPNs constituted the core study group and included those with polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF). Results: A total of 3023 consecutive patients (median age, 62 years; range, 18‐96 years) were considered: 665 PV, 1076 ET, and 1282 PMF. From October 27, 1967, through December 29, 2017, 1631 deaths (54%), 183 leukemic transformations (6%), 244 fibrotic progressions (14%), and 516 thrombotic events (17%) were recorded. Median overall survival (OS) was 18 years for ET, 15 years for PV, and 4.4 years for PMF (P<.05 for all intergroup comparisons). Inferior survival was documented in patients with ET diagnosed more recently (post‐1990) (P<.001), whereas survival data were time independent in PV and PMF. After conventional risk stratification, OS in low‐risk ET and low‐risk PV were superimposed (P=.89) but each differed significantly from that of age‐ and sex‐matched controls (P<.001). Leukemia‐free survival was similar for ET and PV (P=.22) and significantly worse with PMF (P<.001). Compared with ET, PV was associated with higher risk of fibrotic progression (P<.001). Thrombosis risk after diagnosis was highest in PV and lowest in PMF (P=.002 for PV vs ET; P=.56 for ET vs PMF; and P=.001 for PV vs PMF). Conclusion: This study provides the most mature survival and outcomes data in MPNs and highlights MPN subgroup risk categorization as key in appraising disease natural history. The OS was only marginally better in ET compared with PV, and PV displayed a higher risk of thrombosis and fibrotic progression.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.mayocp.2018.08.022

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 3 references

Cited by

See all 168

Metadata

Authors
Szuber, N., Mudireddy, M., Nicolosi, M., Penna, D., Vallapureddy, R. R., Lasho, T. L., Finke, C., Begna, K. H., Elliott, M. A., Hook, C. C., Wolanskyj, A. P., Patnaik, M. M., Hanson, C. A., Ketterling, R. P., Sirhan, S., Pardanani, A., Gangat, N., Busque, L., & Tefferi, A.
Venue
Mayo Clinic Proceedings
Publisher
Elsevier BV
Published
2019-04
Volume
94
Issue
4
Pages
599-610
ISSN
0025-6196 (ISSN-L)
OpenAlex
W2917495513
Cited by
168
References
3
FWCI
7.53
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: 3023 Mayo Clinic Patients With Myeloproliferative Neoplasms: Risk-Stratified Comparison of Survival and Outcomes Data Among Disease Subgroups. https://app.cochat.ai/papers/10.1016/j.mayocp.2018.08.022
The paper
Szuber, N., Mudireddy, M., Nicolosi, M., Penna, D., Vallapureddy, R. R., Lasho, T. L., Finke, C., Begna, K. H., Elliott, M. A., Hook, C. C., Wolanskyj, A. P., Patnaik, M. M., Hanson, C. A., Ketterling, R. P., Sirhan, S., Pardanani, A., Gangat, N., Busque, L., & Tefferi, A. (2019). 3023 Mayo Clinic Patients With Myeloproliferative Neoplasms: Risk-Stratified Comparison of Survival and Outcomes Data Among Disease Subgroups. Mayo Clinic Proceedings. https://doi.org/10.1016/j.mayocp.2018.08.022

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.